University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
NCT Number: NCT03429907
The goal of this research study is to learn if starting a stress-reduction program before treatment can affect your stress, mood, and physical symptoms during and after treatment for cancer.
This is an investigational study.
Up to 140 participants will be enrolled in this study. All participants will be recruited at MD Anderson.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
Female
Interventional
Not applicable
Houston, Texas, 77030, United States
Study Groups:
If you agree to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. You will have an equal chance of being in either group:
Study Visits - All Participants:
Before you start chemotherapy:
At about 15 days after you started the study:
°You will complete one question about your stress. You can complete this question in the clinic or from home on a personal computer.
During chemotherapy:
At about the third month and the sixth month of chemotherapy:
About 6 months after you finish receiving chemotherapy:
Length of Study:
Your participation on this study will be over about 6 months after your last cycle of chemotherapy. If chemotherapy will not be the first treatment you receive for your diagnosis, then your participation on this study will be over at 2 weeks after the start of the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
Other names: Surveys
Time frame: Baseline up to 6 months after chemotherapy
For the primary objective, changes from T0 to T2 and T3 in neurotoxic somatic symptoms analyzed with multilevel models, in which changes over time are estimated simultaneously across groups.
Time frame: Baseline up to 6 months after chemotherapy
To determine the associations of patient-reported outcomes with inflammatory biomarkers, researchers will analyze parallel growth patterns in which correlations between intercept/slope in the PROs and intercept/slope in the biomarkers are tested.
Cortisol assessed in hair samples. In vitro determination of the sensitivity of leukocytes for regulation by cortisol . Blood drawn for plasma levels of biomarkers of immunological activity (C-reactive protein (CRP), IL-6, soluble IL-6 receptor (sIL-6R) TNF-alpha, TNF-receptors I and II (TNF-RI and TNF-RII), and IL-1 receptor antagonist (IL-1RA)), and DAMPs (HSP70, HMGB1, sRAGE). Blood for assessment of cytokine levels in supernatants. Supernatants from T-cells stimulated with anti CD3 and anti CD28 assessed for levels of gamma-interferon, IL-2, IL-10, and IL4. Supernatants from monocytes stimulated with lipopolysaccharide assessed for levels of TNF-alpha and IL-10.
Time frame: Baseline up to 6 months after chemotherapy
Described using cross-sectional Pearson's r correlations and multiple regression models including identified confounding variables.
Cortisol assessed in hair samples. This measure will give insight into the amount of stress experienced in the past month, the time during which the participant was dealing with diagnostic tests and a possible breast cancer diagnosis.
Time frame: Baseline up to 6 months after chemotherapy
Blood for plasma levels of biomarkers of immunological activity (C-reactive protein (CRP), IL-6, soluble IL-6 receptor (sIL-6R) TNF-alpha, TNF-receptors I and II (TNF-RI and TNF-RII), and IL-1 receptor antagonist (IL-1RA)), and DAMPs (HSP70, HMGB1, sRAGE). Blood collected for analysis of mitochondrial function.
Time frame: Baseline up to 6 months after chemotherapy
The ratio of high effort/low effort choices on the EEfRT analyzed with Generalized Estimating Equations (GEE) models, which allow for controlling for time-varying covariates such as trial number.
Time frame: Baseline up to 6 months after chemotherapy
Time frame: Baseline up to 6 months after chemotherapy
To determine the associations of patient-reported outcomes with mitochondrial function, researchers will analyze parallel growth patterns in which correlations between intercept/slope in the PROs and intercept/slope in the biomarkers are tested.
M.D. Anderson Cancer Center
Other
An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer: A Randomized Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02204098
Breast Cancer, Breast Carcinoma
St Louis, Missouri, United States
View Trial DetailsNCT03435952
Breast Diseases, Breast Neoplasms
Houston, Texas, United States
View Trial DetailsNCT03162627
Breast Diseases, Breast Neoplasms
Houston, Texas, United States
View Trial DetailsNCT06495164
Breast Cancer, Breast Diseases
New York, United States
View Trial Details